News - Psychedelic Alpha

New: Explore The Psychedelics Perceptions Tracker.

Read more about the article Psychedelic Investor Survey Q3 2025

Psychedelic Investor Survey Q3 2025

Post published:October 7, 2025
Post category:Analysis News

Read more about the article The Psychedelic News Feed: Sept 29 – Oct 5, 2025

The Psychedelic News Feed: Sept 29 – Oct 5, 2025

Post published:October 6, 2025
Post category:Psychedelic News Feed Archive

Read more about the article Pα+ Psychedelic Bulletin #210: Compass Exec Defends Minimal Support Model in Stockholm; IV Ketamine Outperforms Esketamine Nasal Spray in Retrospective Study; Reunion Advances RE104 in Adjustment Disorder; Mindstate Wraps Phase I

Pα+ Psychedelic Bulletin #210: Compass Exec Defends Minimal Support Model in Stockholm; IV Ketamine Outperforms Esketamine Nasal Spray in Retrospective Study; Reunion Advances RE104 in Adjustment Disorder; Mindstate Wraps Phase I

Post published:October 3, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article The Psychedelic News Feed: September 22 – 28, 2025

The Psychedelic News Feed: September 22 – 28, 2025

Post published:September 29, 2025
Post category:Psychedelic News Feed Archive

Read more about the article Pα+ Psychedelic Bulletin #209: Aussie Insurer Covers Psilocybin for TRD; atai Scores $11.4M NIDA Grant; First Look at Real-World Outcomes from Oregon Psilocybin Clients; Pipeline Updates

Pα+ Psychedelic Bulletin #209: Aussie Insurer Covers Psilocybin for TRD; atai Scores $11.4M NIDA Grant; First Look at Real-World Outcomes from Oregon Psilocybin Clients; Pipeline Updates

Post published:September 24, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Breakthrough Data, Black Box Sessions: A Closer Look at MindMed’s Phase 2b LSD for GAD Study

Breakthrough Data, Black Box Sessions: A Closer Look at MindMed’s Phase 2b LSD for GAD Study

Post published:September 22, 2025
Post category:Analysis News Pα+

Read more about the article UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But Hype Mustn’t Outpace Evidence

UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But Hype Mustn’t Outpace Evidence

Post published:September 19, 2025
Post category:Analysis News Pα+

Read more about the article Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

Post published:September 16, 2025
Post category:2024 Year in Review Analysis

Read more about the article ‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

Post published:September 11, 2025
Post category:Interviews Pα+

Read more about the article August 2025 Psychedelic Patent Update

August 2025 Psychedelic Patent Update

Post published:September 9, 2025
Post category:Psychedelic Patent Analysis Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.